Cytotoxicity and cellular uptake of doxorubicin and its formamidine derivatives in HL60 sensitive and HL60/MX2 resistant cells.
BACKGROUND
In this work a comparison was made of the cytotoxicity and cellular uptake of doxorubicin (DOX) and two of its derivatives containing a formamidino group (-N=CH-N<) at the 3' position with morpholine (DOXM) or hexamethyleneimine (DOXH) ring. All tests were performed in doxorubicin-sensitive HL60 and -resistant HL60/MX2 cells which are known for the presence of altered topoisomerase II.


RESULTS
Cytotoxic activity of DOX toward HL60/MX2 cells was about 195 times lower when compared with the sensitive HL60 cell line. DOXM and DOXH were approximately 20 times more active in resistant cells than DOX. It was found that the uptake of DOX was lower in resistant cells by about 16%, while that of DOXM and DOXH was lower by about 36% and 19%, respectively. Thus the changes in the cellular uptake of anthracyclines are not associated with the fact that cytotoxicity of DOXM and DOXH exceed the cytotoxicity of DOX. Experiments in cell-free system containing human topoisomerase II showed that topoisomerase II is not inhibited by DOXM and DOXH.


CONCLUSIONS
Formamidinoanthracyclines may be more useful than parent drugs in therapy against tumor cells with altered topoisomerase II activity.
Department of Molecular Pharmacology, Medical University of Lodz, 6/8 Mazowiecka St., 92-215 Lodz, Poland.
Krzysztof
K
Kik
Malgorzata
M
Wasowska-Lukawska
Irena
I
Oszczapowicz
Leszek
L
Szmigiero
D000578:Amidines / Q000737:chemistry*; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects*; D004273:DNA, Neoplasm / Q000187:drug effects*; D004317:Doxorubicin / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm; D018922:HL-60 Cells; D006801:Humans; D059005:Topoisomerase II Inhibitors
D000578:Amidines; D000903:Antibiotics, Antineoplastic; D004273:DNA, Neoplasm; D059005:Topoisomerase II Inhibitors; C077922:formamidine; D004317:Doxorubicin